Ripretinib synergized with the MEK inhibitors trametinib and binimetinib in inducing apoptosis in imatinib-sensitive and -resistant GIST and mastocytosis cell lines [9]. This evidence concerns the gene MAP2K7 and gastrointestinal stromal tumor.